
    
      This is an open-label (all people know the identity of the intervention), prospective (in
      which the participants are first identified and then followed forward as time passes),
      observational (study in which the investigators/ physicians observe the patients and measure
      their outcomes), multi-center (study conducted at multiple sites) study. The study mainly
      consists of 2 phases including, the screening phase (14 days before administration of study
      medication) and treatment phase (16 weeks). In the treatment phase, patients will receive
      galantamine 8 mg/day for the first 4 weeks and later on the dose will be increased up to 24mg
      (if tolerable). Safety evaluations will include assessment of adverse events. The total
      duration of the study will be 18 weeks.
    
  